189 related articles for article (PubMed ID: 22590483)
1. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer.
Aapro M; Cornes P; Sun D; Abraham I
Ther Adv Med Oncol; 2012 May; 4(3):95-105. PubMed ID: 22590483
[TBL] [Abstract][Full Text] [Related]
2. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
3. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
4. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
[TBL] [Abstract][Full Text] [Related]
5. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
[TBL] [Abstract][Full Text] [Related]
7. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
10. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
[TBL] [Abstract][Full Text] [Related]
11. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
14. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
15. Glycan analysis of erythropoiesis-stimulating agents.
Cowper B; Lavén M; Hakkarainen B; Mulugeta E
J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
Carrera F; Lok CE; de Francisco A; Locatelli F; Mann JF; Canaud B; Kerr PG; Macdougall IC; Besarab A; Villa G; Kazes I; Van Vlem B; Jolly S; Beyer U; Dougherty FC;
Nephrol Dial Transplant; 2010 Dec; 25(12):4009-17. PubMed ID: 20522670
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
18. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
Muller RJ; Baribeault D
Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
20. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
